Document is current
Any future updates will be listed below
-
Authors
Calabrò, Luana
Morra, Aldo
Cornelissen, Robin
Aerts, Joachim
Maio, Michele
-
Funding
Funding for this research was provided by:
Assiciazione Italiana Ricerca sul Cancro (IG 15373, 2014)
- License Information
-
More Information
Article History
Received: 7 July 2017
Accepted: 22 June 2018
First Online: 26 June 2018
Compliance with ethical standards
:
: Luana Calabrò served on the advisory board of Bristol Myers Squibb; Aldo Morra declares no conflict of interest; Robin Cornelissen served on advisory boards of Boehringer-Ingelheim, Roche, and Lilly; Joachim Aerts served on advisory boards of Eli-Lilly Bristol Myers Squibb, Roche-Genetech, Astra-Zeneca, MSD Sharp & Dohme, and Boehringer Ingelheim, and is a stock owner of Amphera Immunotherapy; Michele Maio served on advisory boards of Bristol Myers Squibb, Roche-Genentech, and AstraZeneca-MedImmune.
: We obtained oral consent from the three patients (reported in the clinical cases) for the description and publication of their cases (including figures).
